about
Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokininA segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrinStructure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.Dendrogenin A and B two new steroidal alkaloids increasing neural responsiveness in the deafened guinea pig.Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds.Exosomes as intercellular signalosomes and pharmacological effectors.Cholesterol-5,6-epoxides: chemistry, biochemistry, metabolic fate and cancer.Cholesterol metabolism and resistance to tamoxifen.Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies.Dendrogenin A: A Mammalian Metabolite of Cholesterol with Tumor Suppressor and Neurostimulating Properties.Improvement of 5,6α-epoxycholesterol, 5,6β-epoxycholesterol, cholestane-3β,5α,6β-triol and 6-oxo-cholestan-3β,5α-diol recovery for quantification by GC/MS.When cholesterol meets histamine, it gives rise to dendrogenin A: a tumour suppressor metabolite.From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite.Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death.Auraptene is an inhibitor of cholesterol esterification and a modulator of estrogen receptors.Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins.Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation.Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism.The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors.High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor.Ligand-induced internalization of cholecystokinin receptors. Demonstration of the importance of the carboxyl terminus for ligand-induced internalization of the rat cholecystokinin type B receptor but not the type A receptor.Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting.Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells.Technical note: Hapten synthesis, antibody production and development of an enzyme-linked immunosorbent assay for detection of the natural steroidal alkaloid Dendrogenin A.Dendrogenin A drives LXR to trigger lethal autophagy in cancers.Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.Role of the extracellular domains of the cholecystokinin receptor in agonist binding.The tumor-suppressor cholesterol metabolite, dendrogenin A, is a new class of LXR modulator activating lethal autophagy in cancers.Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3β,5α-diol (OCDO), a tumor promoter and cholesterol metabolite.Bryonolic Acid Blocks Cancer Cell Clonogenicity and Invasiveness through the Inhibition of Fatty Acid: Cholesteryl Ester Formation.One step synthesis of 6-oxo-cholestan-3β,5α-diol.Quantitative analysis of the tumor suppressor dendrogenin A using liquid chromatography tandem mass spectrometry.Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179HPLC Analysis and Skin Whitening Effects of Umbelliprenin-containing Extracts of , , andThe third intracellular loop of the rat and mouse cholecystokinin-A receptors is responsible for different patterns of gene activationMutation of Asn-391 within the conserved NPXXY motif of the cholecystokinin B receptor abolishes Gq protein activation without affecting its association with the receptorInsights into the cholecystokinin 2 receptor binding site and processes of activation
P50
Q24672870-A1E7B17F-9F0D-46E7-8BB6-56ABB39AC2ADQ28281909-7F770BD6-D61D-4E6E-A824-AE55A1D9CD0AQ33186670-C70B31A5-7028-48CF-B7C3-2CD6205126EBQ35885126-DFCCD010-1EAA-40FC-90CE-84B12EF5381BQ36427475-6A750EBA-5A51-4DEF-8B5F-E8DB1FBDF2D3Q37849358-7EDE8C35-A12C-4884-B0DC-5DA683D38CCEQ38011876-C346644A-EE58-4815-9752-350A2C7E2A22Q38051937-2AD084EF-D6A0-496F-954A-FEF13EACDC56Q38154062-14304CDA-AB04-4BEC-B449-8D1B234B75A3Q38548179-61D72072-456D-44AB-827F-625D0A8E2F9DQ38758291-29758168-269B-4490-B308-26166E165945Q38779028-BFBD7BDC-0402-4070-B90D-3A80CFEBED15Q38854827-A02CAD17-71C9-48B5-8F75-C6F937279485Q39392306-D8EEFFB3-C233-460D-9387-DD0417F86CAEQ39668426-7368F41A-2270-4A24-8F8D-42AFE708C675Q39710091-521E989D-B354-49C4-8D13-6B17BD4748AEQ39788578-F4E1638F-ABA0-48AF-B8BE-851237691631Q39801914-55A92D07-3097-4C10-B183-4224E36970DAQ39906122-153E7530-BFC2-4DFA-AACB-4CFDF929A295Q40256544-EF2EC2E4-E8B0-418F-85BC-144E7CA70823Q42796314-12B3D3B7-4E61-4DDF-8AD4-A771B843470BQ42798520-71C97DDE-A2D9-4657-9EA4-ADFBF1A9B6EFQ42825863-B8D1FF24-5C12-4C1D-A54D-2C249B07AE1DQ43255676-934FF0C4-7594-4A75-9BD1-503DF29EB2D5Q44655945-25A3B2E0-E0C0-4FC0-9B28-791FDBFF408FQ44895295-307B8D5C-6D89-42A4-B166-C7ED7B5D61A5Q47107657-E079930E-4FD1-4EB2-A59A-37EE05950D0BQ47594502-1DB27038-8F77-4184-80FC-71EFC6F2E894Q47752753-0E6439E3-1E9F-4720-9E8A-BE5DAC3DB94DQ50153633-B9CEEA46-829F-4F7A-8272-77D66644D6E2Q51681745-C1D45801-D502-45CF-A928-DE2E9B6A3311Q52588693-9E58781B-7115-4819-8C8B-C2EA261A3D74Q52695559-01EFF1BF-E586-44DF-995E-D23B388C486AQ53242479-44302ACA-FACB-417C-9AC3-4AD70C7F6719Q53981196-61C3E4E4-BA7D-47F0-B7F6-10BA72FA4C3DQ58105124-59B5D4CD-3CBE-46B5-959D-5700BE5CD5E7Q64269219-56934955-E9F0-44B6-A072-F8AF09BD1CA9Q73229782-C991C3E1-2845-4FA9-8D4B-89E6EF0D3ADFQ73626826-A17B1372-C3BC-45D8-8D00-B876508AD37DQ80335630-F7AE2342-04AB-4A6A-94E6-98357EA5C030
P50
description
researcher
@en
wetenschapper
@nl
name
Sandrine Silvente-Poirot
@br
Sandrine Silvente-Poirot
@co
Sandrine Silvente-Poirot
@da
Sandrine Silvente-Poirot
@de
Sandrine Silvente-Poirot
@en
Sandrine Silvente-Poirot
@es
Sandrine Silvente-Poirot
@fr
Sandrine Silvente-Poirot
@id
Sandrine Silvente-Poirot
@it
Sandrine Silvente-Poirot
@nds
type
label
Sandrine Silvente-Poirot
@br
Sandrine Silvente-Poirot
@co
Sandrine Silvente-Poirot
@da
Sandrine Silvente-Poirot
@de
Sandrine Silvente-Poirot
@en
Sandrine Silvente-Poirot
@es
Sandrine Silvente-Poirot
@fr
Sandrine Silvente-Poirot
@id
Sandrine Silvente-Poirot
@it
Sandrine Silvente-Poirot
@nds
altLabel
S Silvente Poirot
@en
prefLabel
Sandrine Silvente-Poirot
@br
Sandrine Silvente-Poirot
@co
Sandrine Silvente-Poirot
@da
Sandrine Silvente-Poirot
@de
Sandrine Silvente-Poirot
@en
Sandrine Silvente-Poirot
@es
Sandrine Silvente-Poirot
@fr
Sandrine Silvente-Poirot
@id
Sandrine Silvente-Poirot
@it
Sandrine Silvente-Poirot
@nds
P106
P21
P31
P496
0000-0003-2245-9069